Assessments of AR-V7 mRNA in circulating tumor cells (CTC) (3) showed that the presence of AR-V7 mRNA in CTCs was associated with increased resistance to AR-targeting therapies and that AR-V7 mRNA may be a treatment selection marker in patients with CRPC (4–9). This evidence concerns the gene AR and neoplasm.